Suppression of experimental uveitis by a recombinant adeno-associated virus vector encoding interleukin-1 receptor antagonist.
OBJECTIVE
To evaluate the potential of gene therapy with a recombinant adeno-associated virus vector encoding the interleukin-1 receptor antagonist gene (rAAV-IL-1Ra) in the treatment of experimental uveitis.


METHODS
The vitreal cavity of New Zealand white rabbits was injected with rAAV-IL-1Ra (4x10(7) infectious units), and the contralateral eye was injected with the same amount of rAAV-LacZ or PBS as a control. Transgene expression was evaluated by immunohistochemistry, ELISA, and RT-PCR. To evaluate the therapeutic potential of rAAV-IL-1Ra, experimental uveitis was induced by intravitreal injection of IL-1alpha at 10 and 100 days after rAAV-IL-1Ra administration. The effects of rAAV-IL-1Ra on experimental uveitis were investigated using histological and aqueous analysis.


RESULTS
Following intravitreal injection of rAAV-IL-1Ra, transgene expression was found in various cell types of the ocular tissues, such as ciliary epithelial cells, retinal ganglion cells, and retinal pigment epithelial cells. RT-PCR and ELISA showed that the IL-1Ra transgene persisted in the rabbit eye for at least 100 days. Compared with the control eyes, the transgene expression ameliorated experimental uveitis at 10 and 100 days after a single administration of rAAV-IL-1Ra.


CONCLUSIONS
Intravitreal administration of rAAV-IL-1Ra led to sustained human IL-1Ra transgene expression in rabbit eyes for 100 days. The transgene expression suppressed uveitis episodes at 10 and 100 days after rAAV-IL-1Ra injection. Long-term suppression of experimental uveitis could be achieved by gene therapy with rAAV-IL-1Ra.
Tsai
Ming-Ling
ML
Department of Ophthalmology, Tri-Service General Hospital, Taipei, Taiwan.
Horng
Chi-Ting
CT
Chen
Show-Li
SL
Xiao
Xiao
X
Wang
Chih-Hung
CH
Tsao
Yeou-Ping
YP
D000818:Animals; D001082:Aqueous Humor / Q000378:metabolism; D000229:Dependovirus / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D005786:Gene Expression Regulation; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007267:Injections; D053590:Interleukin 1 Receptor Antagonist Protein / Q000008:administration & dosage / Q000235:genetics* / Q000627:therapeutic use*; D011817:Rabbits; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D019076:Transgenes; D014605:Uveitis / Q000139:chemically induced / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control*
D053590:Interleukin 1 Receptor Antagonist Protein
Invest Ophthalmol Vis Sci. 1996 Jun;37(7):1282-93
8641831
Nature. 1990 Apr 12;344(6267):633-8
2139180
Arch Ophthalmol. 1996 May;114(5):593-9
8619771
Mol Ther. 2004 Jul;10(1):106-16
15233947
Nature. 1990 Jan 25;343(6256):341-6
2137201
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1823-6
10845604
Cytokine. 1992 Sep;4(5):353-60
1420996
Rheum Dis Clin North Am. 1998 Aug;24(3):615-28
9710890
J Gene Med. 2008 Apr;10(4):375-82
18278824
Arch Ophthalmol. 1996 Aug;114(8):1000-1
8694704
J Virol. 2001 Aug;75(15):6969-76
11435577
Ophthalmic Res. 2008;40(3-4):200-2
18421239
Arch Ophthalmol. 1999 Oct;117(10):1414-8
10532455
Arch Ophthalmol. 2005 Jul;123(7):957-63
16009838
Exp Neurol. 1997 Mar;144(1):113-24
9126160
Gynecol Oncol. 2003 Apr;89(1):77-83
12694657
Curr Eye Res. 2000 Mar;20(3):211-4
10694897
J Virol. 2008 Aug;82(16):7875-85
18524821
Biol Chem. 1999 Jun;380(6):613-22
10430026
Dermatol Clin. 1992 Jul;10(3):505-12
1617809
Invest Ophthalmol Vis Sci. 1999 Nov;40(12):3041-6
10549671
Mol Vis. 2008 Sep 24;14:1760-9
18836574
Invest Ophthalmol Vis Sci. 1994 Mar;35(3):1107-13
8125721
Immunol Rev. 1982;63:51-72
6804369
Arch Ophthalmol. 1992 Apr;110(4):547-9
1532889
Mol Vis. 2004 Feb 10;10:93-102
14961006
Arch Ophthalmol. 1962 Oct;68:502-14
13883604
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):751-7
11867594
Invest Ophthalmol Vis Sci. 1994 May;35(6):2662-6
8188460
Arch Ophthalmol. 1987 Aug;105(8):1117-20
3498471
Transplantation. 1997 May 27;63(10):1501-7
9175817
Ophthalmologica. 1999;213(5):300-4
10516518
J Ocul Pharmacol Ther. 1997 Oct;13(5):427-33
9326724
Curr Eye Res. 1987 Jul;6(7):929-34
3040339
Hum Gene Ther. 1998 Jan 1;9(1):81-6
9458245
Rheumatol Int. 2005 Jan;25(1):1-5
14600787
Chem Immunol. 1999;73:90-119
10590576
J Virol. 1999 Apr;73(4):3410-7
10074195
Invest Ophthalmol Vis Sci. 2001 Sep;42(10):2401-7
11527956
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13714-9
11095710
Exp Eye Res. 1998 May;66(5):547-57
9628802
Vision Res. 2008 Feb;48(3):353-9
17923143
Nat Med. 1996 May;2(5):545-50
8616713
Arthritis Rheum. 2000 Feb;43(2):289-97
10693868
Mol Vis. 2008;14:1845-9
18941541
Curr Eye Res. 1997 Sep;16(9):949-56
9288458